Geron Corporation (GERN) Highlights Presentations at American Society of Clinical Oncology/American Association for Cancer Research Joint Session
Tweet Send to a FriendGet Alerts GERN Hot Sheet
Trade GERN Now!
Geron Corporation (Nasdaq: GERN) highlights presentations at the American Society of Clinical Oncology/American Association for Cancer Research Joint Session: Telomeres and Telomerase in Cancer taking place today at the 2011 ASCO Annual Meeting in Chicago, IL.
The special session will be co-chaired by ASCO’s outgoing president, George W. Sledge, M.D., and Elizabeth H. Blackburn, Ph.D.
The joint session will begin at 9:45 a.m. CDT, and a webcast will be available for conference registrants.
Presenting at the Joint Session will be Kathy D. Miller, M.D., Associate Professor and Sheila D. Ward Scholar at the Indiana University Melvin and Bren Simon Cancer Center.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The special session will be co-chaired by ASCO’s outgoing president, George W. Sledge, M.D., and Elizabeth H. Blackburn, Ph.D.
The joint session will begin at 9:45 a.m. CDT, and a webcast will be available for conference registrants.
Presenting at the Joint Session will be Kathy D. Miller, M.D., Associate Professor and Sheila D. Ward Scholar at the Indiana University Melvin and Bren Simon Cancer Center.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Supreme Court Reverses U.S. Court of Appeals Decision in FTC v. Actavis (ACT)
- Ascent Solar (ASTI) Enters $6M Private Placement Agreement
- TransDigm (TDG) Considers $1-$1.8B Special Dividend; Requests to Amend Credit Facility
Create E-mail Alert Related Categories
Corporate NewsLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

Down)